Biodesix (BDSX) Aandelenoverzicht
Biodesix, Inc. is actief als bedrijf voor diagnostische oplossingen. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
BDSX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Biodesix, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$21.99 |
| 52 Week Hoogtepunt | US$24.92 |
| 52 Week Laag | US$5.26 |
| Bèta | 0.52 |
| 1 maand verandering | 42.24% |
| 3 maanden verandering | 43.16% |
| 1 Jaar Verandering | 304.82% |
| 3 jaar verandering | -7.61% |
| 5 jaar verandering | -90.79% |
| Verandering sinds IPO | -91.42% |
Recent nieuws en updates
Narratiefupdate • Jun 25
BDSX: Durable Gross Margins And EBITDA Breakeven Path Will Support Higher Confidence
The analyst price target for Biodesix has been revised modestly higher from about $30.50 to roughly $30.83, with analysts pointing to expectations for durable top line growth, strong gross margins, and a path toward adjusted EBITDA breakeven as key supports for the updated view. Analyst Commentary Recent research on Biodesix highlights a generally constructive stance, with price targets clustered in the high $20s to low $30s and commentary focused on growth, margins, and the path to adjusted EBITDA breakeven.
Narratiefupdate • Jun 11
BDSX: Larger Lung Nodule Study And 2026 Guidance Will Support Upside
Analysts have raised their price target on Biodesix by $2 to $22, citing updated expectations around fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Biodesix raised its consolidated earnings guidance for fiscal 2026, now expecting total revenue of US$108–114 million versus prior guidance of US$106–112 million, with the midpoint implying approximately 25% growth over 2025 compared with the earlier midpoint of 23% growth.Narratiefupdate • May 28
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Higher Confidence
Analysts nudged their Biodesix price target higher by $0.50 to $30.50, citing Street research that highlights slightly adjusted growth and discount rate assumptions, better profit margin expectations, and recent upgrades tied to revenue guidance and an improved balance sheet. Analyst Commentary Recent Street research gives you a mixed but constructive picture of how analysts are thinking about Biodesix, with some focusing on execution and balance sheet progress, and others more cautious around what is already reflected in the valuation.
Narratiefupdate • May 02
BDSX: Improved Balance Sheet And 2026 Revenue Outlook Will Support Upside
Analysts have lifted their price target on Biodesix to $73.88 from $57.08, citing above-expectation 2026 revenue guidance, three consecutive quarters of execution above target, and a "significantly improved" balance sheet that together support a higher assumed future P/E multiple. Analyst Commentary Recent research commentary points to a more constructive view on Biodesix, with bullish analysts highlighting the company’s 2026 revenue guidance, operating execution, and balance sheet as key reasons for a higher valuation framework.Recent updates
Narratiefupdate • Jun 25
BDSX: Durable Gross Margins And EBITDA Breakeven Path Will Support Higher Confidence
The analyst price target for Biodesix has been revised modestly higher from about $30.50 to roughly $30.83, with analysts pointing to expectations for durable top line growth, strong gross margins, and a path toward adjusted EBITDA breakeven as key supports for the updated view. Analyst Commentary Recent research on Biodesix highlights a generally constructive stance, with price targets clustered in the high $20s to low $30s and commentary focused on growth, margins, and the path to adjusted EBITDA breakeven.Narratiefupdate • Jun 11
BDSX: Larger Lung Nodule Study And 2026 Guidance Will Support Upside
Analysts have raised their price target on Biodesix by $2 to $22, citing updated expectations around fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Biodesix raised its consolidated earnings guidance for fiscal 2026, now expecting total revenue of US$108–114 million versus prior guidance of US$106–112 million, with the midpoint implying approximately 25% growth over 2025 compared with the earlier midpoint of 23% growth.Narratiefupdate • May 28
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Higher Confidence
Analysts nudged their Biodesix price target higher by $0.50 to $30.50, citing Street research that highlights slightly adjusted growth and discount rate assumptions, better profit margin expectations, and recent upgrades tied to revenue guidance and an improved balance sheet. Analyst Commentary Recent Street research gives you a mixed but constructive picture of how analysts are thinking about Biodesix, with some focusing on execution and balance sheet progress, and others more cautious around what is already reflected in the valuation.Narratiefupdate • May 02
BDSX: Improved Balance Sheet And 2026 Revenue Outlook Will Support Upside
Analysts have lifted their price target on Biodesix to $73.88 from $57.08, citing above-expectation 2026 revenue guidance, three consecutive quarters of execution above target, and a "significantly improved" balance sheet that together support a higher assumed future P/E multiple. Analyst Commentary Recent research commentary points to a more constructive view on Biodesix, with bullish analysts highlighting the company’s 2026 revenue guidance, operating execution, and balance sheet as key reasons for a higher valuation framework.Narratiefupdate • Apr 16
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upgraded Rating
Analysts have nudged their price target on Biodesix higher to $30.00 from $30, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and three consecutive quarters of execution above target as reasons for a more constructive view. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to an Outperform rating as a signal that recent execution and guidance support a higher valuation framework than before.Narratiefupdate • Apr 01
BDSX: Strong Guidance And Healthier Balance Sheet Will Support 2026 Momentum
Analysts have raised their price target on Biodesix from $30.00 to $56.14, citing 2026 revenue guidance that is 3% above prior expectations and a "significantly improved" balance sheet, with execution running above target for three consecutive quarters. Analyst Commentary Bullish Takeaways Bullish analysts point to the 2026 revenue guidance coming in 3% above prior expectations as support for a higher valuation range, given that it directly feeds into forward revenue estimates and P/S assumptions.Narratiefupdate • Mar 18
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upside
Analysts have maintained their price target on Biodesix, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and what they see as three consecutive quarters of above target execution heading into 2026. Analyst Commentary The latest upgrade frames Biodesix as entering 2026 with momentum, supported by revenue guidance that sits 3% ahead of expectations and an improved balance sheet.Narratiefupdate • Mar 04
BDSX: Improved Balance Sheet And Guidance Will Support Momentum Into 2026
Analysts have reduced their price target on Biodesix from $35 to $30, citing updated fair value assumptions along with views that recent revenue guidance, improving margins, and a lower discount rate better reflect the company’s execution and balance sheet strength. Analyst Commentary Bullish Takeaways Bullish analysts point to the upgrade to an Outperform rating as a sign that recent execution and guidance are more in line with what they view as fair value.Narratiefupdate • Feb 18
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have revised their price target on Biodesix to $40.00 from $40, reflecting updated views on discount rate, revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Biodesix raised its revenue guidance for the fiscal year ending December 31, 2025, estimating total revenue of $88.5 million, above the previously increased range of $84 million to $86 million (company guidance).Narratiefupdate • Feb 02
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have adjusted their price target on Biodesix to US$40.00 from US$40, citing updated assumptions around discount rates, revenue growth, profit margin, and future P/E that collectively refine, rather than overhaul, their previous view. What's in the News Biodesix issued new earnings guidance for the fourth quarter ended December 31, 2025, estimating total revenue of US$28.8 million for the period (Key Developments).Narratiefupdate • Jan 19
BDSX: Expanded Diagnostics Partnership Will Drive Revenue Upside In 2025
Analysts have increased their price target on Biodesix to reflect updated views on revenue growth potential and a slightly lower discount rate, while also adjusting expected profit margins and future P/E assumptions to align with their latest models. What's in the News Biodesix issued earnings guidance for the fourth quarter of 2025, estimating total revenue of $28.8 million for the period (Corporate guidance).Analyseartikel • Jan 14
Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump
Despite an already strong run, Biodesix, Inc. ( NASDAQ:BDSX ) shares have been powering on, with a gain of 26% in the...Narratiefupdate • Jan 05
BDSX: Expanded Diagnostics Partnership And ESR1 Assay Rollout Will Drive Upside
Analysts have lifted their price target on Biodesix to US$20.00 from US$1.50, citing adjusted assumptions around revenue growth, profit margin, discount rate, and a lower future P/E multiple as the key drivers of this revised view. What's in the News Biodesix raised its fiscal 2025 revenue guidance and now expects total revenue between US$84 million and US$86 million for the year (Key Developments).Narratiefupdate • Dec 14
BDSX: Reverse Split And ATM Access Will Support Path To Profitability
Analysts have significantly lifted their price target on Biodesix from $2.00 to $40.00, citing updated models following the 20 for 1 reverse split, a reduced share count, and the company’s ability to utilize its at the market facility to support operations through an expected path to cash flow breakeven and profitability. Analyst Commentary Bullish analysts interpret the new price target framework as a constructive signal for Biodesix, emphasizing that the reset reflects mechanical impacts from the 20 for 1 reverse split rather than a fundamental deterioration in the business outlook.Analyseartikel • Nov 29
Biodesix, Inc.'s (NASDAQ:BDSX) Shares Leap 27% Yet They're Still Not Telling The Full Story
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Analyseartikel • Nov 05
US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results
Biodesix, Inc. ( NASDAQ:BDSX ) just released its latest quarterly results and things are looking bullish. Revenues and...Analyseartikel • Sep 18
It's Down 27% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 27% over the previous 30 days, handing back...Narratiefupdate • Sep 16
Digital Integration And Expanded Lung Diagnostics Will Broaden Markets
The substantial increase in Biodesix’s consensus price target is accompanied by a modest improvement in forward earnings valuation and a slight rise in discount rate, indicating more favorable future expectations despite a marginally higher cost of capital, with fair value rising markedly to $35.00. What's in the News Biodesix announced a 1-for-20 stock split.Analyseartikel • Jul 29
The Market Lifts Biodesix, Inc. (NASDAQ:BDSX) Shares 67% But It Can Do More
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 67% in the...Analyseartikel • Jun 14
Biodesix, Inc. (NASDAQ:BDSX) Stock Rockets 30% But Many Are Still Ignoring The Company
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 30% in the...Analyseartikel • May 15
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers
The latest analyst coverage could presage a bad day for Biodesix, Inc. ( NASDAQ:BDSX ), with the analysts making...Analyseartikel • May 14
It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year
Key Insights Biodesix's Annual General Meeting to take place on 20th of May Salary of US$588.9k is part of CEO Scott...Analyseartikel • Apr 19
Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 33% in the last...
Nieuw narratief • Apr 03
Sales Force Expansion And CLARIFY Study Will Boost Test Adoption
Expansion of sales force and test adoption, along with CLARIFY study results, are expected to drive revenue growth and improve margins.Analyseartikel • Mar 05
It's Down 30% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 30% in the last...Analyseartikel • Jan 19
The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27%
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Analyseartikel • Nov 21
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 26% in the last...Analyseartikel • Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Analyseartikel • Mar 03
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 25% over the previous 30 days, handing back...Analyseartikel • Jan 04
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...Analyseartikel • Jul 16
It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 28% in the last...Rendement voor aandeelhouders
| BDSX | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | -5.8% | 2.0% | 1.6% |
| 1Y | 304.8% | 28.7% | 18.6% |
Rendement versus industrie: BDSX overtrof de US Healthcare industrie, die het afgelopen jaar een rendement 28.7 % opleverde.
Rendement versus markt: BDSX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 18.6 %.
Prijsvolatiliteit
| BDSX volatility | |
|---|---|
| BDSX Average Weekly Movement | 15.4% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: De aandelenkoers van BDSX is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 15% ) van BDSX is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2005 | 334 | Scott Hutton | www.biodesix.com |
Biodesix, Inc. is een bedrijf dat diagnostische oplossingen biedt. Het bedrijf biedt longtests op basis van bloed, waaronder Nodify XL2- en Nodify CDT-tests als Nodify Lung Nodule Risk Assessment-tests om het risico op longkanker te beoordelen en te helpen bij het identificeren van het juiste behandeltraject en artsen te helpen bij het herclassificeren van het risico op maligniteit bij patiënten met verdachte longknobbels. Het bedrijf levert ook GeneStrat ddPCR-, GeneStrat NGS- en VeriStrat-tests als onderdeel van de IQLung-teststrategie, die worden gebruikt bij de diagnose van longkanker om de aanwezigheid van mutaties in de tumor en de toestand van het immuunsysteem van de patiënt te meten om beslissingen over de behandeling te sturen.
Biodesix, Inc. Samenvatting
| BDSX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$222.29m |
| Inkomsten(TTM) | -US$31.96m |
| Inkomsten(TTM) | US$96.10m |
2.3x
P/S-verhouding-7.0x
Koers/WinstverhoudingIs BDSX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| BDSX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$96.10m |
| Kosten van inkomsten | US$17.62m |
| Brutowinst | US$78.48m |
| Overige uitgaven | US$110.43m |
| Inkomsten | -US$31.96m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.16 |
| Brutomarge | 81.66% |
| Nettowinstmarge | -33.26% |
| Schuld/Eigen Vermogen Verhouding | 509.1% |
Hoe presteerde BDSX op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/05 04:06 |
| Aandelenkoers aan het einde van de dag | 2026/07/02 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Biodesix, Inc. wordt gevolgd door 10 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| William Bonello | Craig-Hallum Capital Group LLC |